CRDF Projected Dividend Yield

Cardiff Oncology Inc ( NASDAQ : CRDF )

Cardiff Oncology is a clinical-stage oncology company. Co.'s clinical development programs incorporate tumor genomics and biomarker assays to refine assessment of patient response to treatment. Onvansertib, Co.'s primary compound, is a highly selective Polo-like Kinase 1 (PLK1) inhibitor. PLK1, a serine/threonine kinase, has a mechanism of action within tumor cell proliferation and is overexpressed in a number of tumors (including colorectal, pancreatic, prostate, ovarian, breast and lung cancer). In particular, PLK1's activity in various phases of the cell cycle provide multiple targets for a PLK1 inhibitor to inhibit DNA repair and interrupt cell division, thereby killing tumor cells.

20 YEAR PERFORMANCE RESULTS